Drug
Fcn 159
Fcn 159: highest development phase Phase 2, developed by Shanghai Fosun Pharmaceutical. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Shanghai Fosun Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| FCN-159 NCT05997602 | Phase 2 | Langerhans Cell Histiocytosis |
| FCN-159 NCT06913725 | Phase 2 | Brain Arteriovenous Malformations |
| FCN-159 NCT04954001 | Phase 1/2 | Neurofibromatosis 1 |
Latest
No recent events.
Follow Fcn 159 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.